CR20200546A - ESTIMULADOR SELECTIVO TREG RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS - Google Patents

ESTIMULADOR SELECTIVO TREG RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS

Info

Publication number
CR20200546A
CR20200546A CR20200546A CR20200546A CR20200546A CR 20200546 A CR20200546 A CR 20200546A CR 20200546 A CR20200546 A CR 20200546A CR 20200546 A CR20200546 A CR 20200546A CR 20200546 A CR20200546 A CR 20200546A
Authority
CR
Costa Rica
Prior art keywords
rur20kd
related compositions
compositions
treg stimulator
selective treg
Prior art date
Application number
CR20200546A
Other languages
English (en)
Inventor
Jonathan Zalevsky
Peter Benedict Kirk
John L Langowski
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of CR20200546A publication Critical patent/CR20200546A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente divulgación proporciona composiciones de estimulador de Treg selectivo, que incluyen RUR<sub>20kD</sub>-IL-2 y composiciones relacionadas, y métodos de uso de estas composiciones, por ejemplo, para tratar enfermedades autoinmunitarias y/u otras afecciones que responden al tratamiento que es eficaz para proporcionar un aumento de las cantidades y la activación de los linfocitos T reguladores sobre los linfocitos T efectores.
CR20200546A 2018-05-21 2019-05-20 ESTIMULADOR SELECTIVO TREG RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS CR20200546A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862674244P 2018-05-21 2018-05-21
PCT/US2019/033100 WO2019226538A1 (en) 2018-05-21 2019-05-20 SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS

Publications (1)

Publication Number Publication Date
CR20200546A true CR20200546A (es) 2021-05-18

Family

ID=67002369

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200546A CR20200546A (es) 2018-05-21 2019-05-20 ESTIMULADOR SELECTIVO TREG RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS

Country Status (19)

Country Link
US (1) US20210205413A1 (es)
EP (1) EP3796940A1 (es)
JP (3) JP7235772B2 (es)
CN (1) CN112399859A (es)
AU (2) AU2019274409B2 (es)
BR (1) BR112020021564A2 (es)
CA (1) CA3100204A1 (es)
CL (1) CL2020003008A1 (es)
CO (1) CO2020014510A2 (es)
CR (1) CR20200546A (es)
DO (1) DOP2020000212A (es)
EA (1) EA202092489A1 (es)
EC (1) ECSP20074392A (es)
IL (2) IL312646A (es)
JO (1) JOP20200290A1 (es)
PE (1) PE20211307A1 (es)
PH (1) PH12020551976A1 (es)
SG (1) SG11202011242SA (es)
WO (1) WO2019226538A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115315436A (zh) 2020-01-10 2022-11-08 明峰治疗股份公司 修饰的il-2多肽及其用途
CN113121670B (zh) * 2020-01-15 2022-11-22 天津键凯科技有限公司 二取代peg化白细胞介素2及其制备方法、应用
WO2021143572A1 (zh) * 2020-01-15 2021-07-22 天津键凯科技有限公司 一种制备结合位点可控的peg化生物分子的方法
JP2021143142A (ja) * 2020-03-11 2021-09-24 花王株式会社 制御性ｔ細胞誘導剤
WO2021236474A1 (en) * 2020-05-22 2021-11-25 Merck Sharp & Dohme Corp. Novel processes for preparing conjugates of the il-2 protein
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
WO2022109477A1 (en) * 2020-11-23 2022-05-27 University Of Florida Research Foundation, Incorporated Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes
KR20240123817A (ko) 2021-12-14 2024-08-14 넥타르 테라퓨틱스 선택적 TREG 자극제 RUR20kD-IL-2를 위한 투여 계획 및 관련 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401756A (en) 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5153310A (en) 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
FR2826365B1 (fr) 2001-06-20 2003-09-26 Oreal Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile
PT2644206T (pt) 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
US7567215B1 (en) 2007-10-23 2009-07-28 The United States Of America As Represented By The Secretary Of The Navy Portable and inflatable antenna device
RS61854B1 (sr) * 2010-11-12 2021-06-30 Nektar Therapeutics Konjugati il-2 dela i polimera
EP3766513A1 (en) * 2011-03-11 2021-01-20 Assistance Publique Hôpitaux de Paris Use of low dosage il-2 for treating vasculitis
EP3431096A4 (en) * 2016-03-16 2020-01-15 Xie, Yanhui GLUCOCORTICOID COMBINED WITH INTERLEUKIN-2 MODIFIED BY POLYETHYLENE GLYCOL TO TREAT RESPIRATORY DISEASE

Also Published As

Publication number Publication date
WO2019226538A1 (en) 2019-11-28
PH12020551976A1 (en) 2021-09-13
AU2022246440A1 (en) 2022-11-03
IL312646A (en) 2024-07-01
JP2023052053A (ja) 2023-04-11
JOP20200290A1 (ar) 2020-11-15
CA3100204A1 (en) 2019-11-28
IL278528A (es) 2021-01-31
AU2019274409A1 (en) 2020-11-12
CO2020014510A2 (es) 2021-03-08
US20210205413A1 (en) 2021-07-08
DOP2020000212A (es) 2021-03-15
IL278528B1 (en) 2024-06-01
SG11202011242SA (en) 2020-12-30
ECSP20074392A (es) 2021-03-31
JP7235772B2 (ja) 2023-03-08
EA202092489A1 (ru) 2021-03-16
AU2019274409B2 (en) 2022-07-14
CL2020003008A1 (es) 2021-07-30
PE20211307A1 (es) 2021-07-20
CN112399859A (zh) 2021-02-23
JP2024116272A (ja) 2024-08-27
JP2021523922A (ja) 2021-09-09
BR112020021564A2 (pt) 2021-03-02
KR20210002577A (ko) 2021-01-08
EP3796940A1 (en) 2021-03-31

Similar Documents

Publication Publication Date Title
PH12020551976A1 (en) SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS
WO2020086726A3 (en) Nerve stimulation for treating migraine and other headache conditions
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
ZA201804513B (en) Method of treating c3 glomerulopathy
MX2022011546A (es) Composiciones y metodos para el agotamiento de celulas cd137+.
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
EA201791518A1 (ru) Способы лечения заболеваний сетчатки
MX2020011817A (es) Metodos para tratar el linfoma.
NZ741785A (en) 3-cyano-1h-1,2,4-triazol-1-yl compounds and uses thereof for the treatment of hiv
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
WO2019157495A3 (en) Methods for preventing and/or treating bone loss conditions by modulating irisin
MX2019013862A (es) Terapia de combinacion.
MX2021014905A (es) Células seguras e invisibles para el sistema inmunitario.
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
MX2020011263A (es) Metodos y composiciones de agotamiento de celulas t citotoxicas.
MX2022004373A (es) Celulas madre modificadas y metodos de uso de las mismas.
MX2020007366A (es) Composiciones y metodos para tratar trastornos de la retina.
MX2020013621A (es) Composiciones y metodos de tratamiento de vih.
MX2021002982A (es) Composiciones y metodos para tratar retinitis pigmentosa.
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
WO2020049552A9 (en) Tissue repair by activated cells
WO2018231025A3 (ko) 면역세포 이동에 의한 질환의 치료제 및 이의 스크리닝 방법